Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Oral midazolam for care refusal in older adults with severe neurocognitive disorders
2023-510277-33-00Phase 2Authorised
- Sponsor
- CHU Grenoble Alpes
- Start
- May 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of midazolam in cognitive disorder (CD), sponsored by CHU Grenoble Alpes. Primary endpoint: Primary efficacy endpoint. Planned start May 2025; status: authorised.
02
Drugs
midazolam
03
Conditions
cognitive disorder (CD)
Beyond the preview
Go deeper on 2023-510277-33-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-510277-33-00.